Repare Therapeutics Inc (RPTX)

May 19, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) is MPM Asset Management LLC's 6th Largest Position - MarketBeat

May 19, 2025

May 19, 2025

MPM Bioimpact LLC Sells 408,695 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - MarketBeat

May 19, 2025

May 16, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Stifel Financial Corp - Defense World

May 16, 2025

May 14, 2025

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News

May 14, 2025

May 14, 2025

RPTX Advances Pipeline with Strategic Partnership | RPTX Stock N - GuruFocus

May 14, 2025

May 14, 2025

Tower Research Capital LLC TRC Purchases 23,127 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 14, 2025

May 13, 2025

Repare Therapeutics Provides Business - citybiz

May 13, 2025

May 13, 2025

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results - ADVFN

May 13, 2025

May 13, 2025

Repare Therapeutics Provides Business and Clinical Update and Re - GuruFocus

May 13, 2025

May 13, 2025

Repare Therapeutics Advances Strategic Partnerships and Clinical Trials Amid Financial Updates - TipRanks

May 13, 2025

May 07, 2025

Repare Therapeutics Inc’s Market Journey: Closing Weak at 1.33, Down -5.00 - DWinneX

May 07, 2025

May 07, 2025

Marshall Wace LLP Decreases Stake in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 07, 2025

May 06, 2025

JPMorgan Chase & Co. Boosts Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 06, 2025

May 04, 2025

Renaissance Technologies LLC Has $455,000 Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 04, 2025

May 02, 2025

Repare signs out-licensing deal with DCx Biotherapeutics - Yahoo

May 02, 2025

May 01, 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - CRISPR Medicine News

May 01, 2025

May 01, 2025

Repare Therapeutics Inc. Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - marketscreener.com

May 01, 2025

May 01, 2025

Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News

May 01, 2025

May 01, 2025

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates - BioSpace

May 01, 2025

Apr 29, 2025

Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

Apr 29, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 25, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Significant Drop in Short Interest - MarketBeat

Apr 25, 2025

Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 - CRISPR Medicine News

Apr 25, 2025

Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Present - GuruFocus

Apr 25, 2025

Apr 24, 2025

Do investors need to be concerned about Repare Therapeutics Inc (RPTX)? - uspostnews.com

Apr 24, 2025

Apr 24, 2025

Insider’s View: Deciphering Repare Therapeutics Inc (RPTX)’s Financial Health Through Ratios - DWinneX

Apr 24, 2025

Apr 23, 2025

Repare Therapeutics Inc (RPTX) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Apr 23, 2025

Apr 21, 2025

B. Riley Cuts Price Target on Repare Therapeutics to $4 From $5, Keeps Buy Rating - marketscreener.com

Apr 21, 2025

Apr 16, 2025

Cathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare Therapeutics - Investing.com UK

Apr 16, 2025

Apr 12, 2025

Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock By Investing.com - Investing.com India

Apr 12, 2025

Apr 11, 2025

Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - Benzinga

Apr 11, 2025

Apr 11, 2025

Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga

Apr 11, 2025

Apr 11, 2025

Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock - Investing.com

Apr 11, 2025

Apr 04, 2025

Repare Therapeutics Stock Hits 52-Week Low at $0.98 Amid Market Challenges - Investing.com

Apr 04, 2025

Apr 03, 2025

Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals

Apr 03, 2025

Apr 01, 2025

Repare Therapeutics details discovery of PLK4 inhibitor RP-1664 - BioWorld MedTech

Apr 01, 2025

Mar 31, 2025

Repare Therapeutics Appoints Steve Forte CEO - citybiz

Mar 31, 2025

Mar 31, 2025

Repare Therapeutics appoints CFO as new CEO - MSN

Mar 31, 2025

Mar 31, 2025

Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal - MarketScreener

Mar 31, 2025

Mar 31, 2025

Repare Therapeutics Announces Leadership Changes in 2025 - TipRanks

Mar 31, 2025

Mar 31, 2025

Repare Therapeutics Names Forte as President, CEO - MarketWatch

Mar 31, 2025

Mar 31, 2025

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds - TipRanks

Mar 31, 2025

Mar 31, 2025

Repare's New CEO Takes Helm With 3 Clinical Trial Readouts Coming in 2025 - Stock Titan

Mar 31, 2025

Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025

Mar 31, 2025

Repare Therapeutics Announces Leadership Transitions - Business Wire

Mar 31, 2025